JP2019532970A5 - - Google Patents

Info

Publication number

JP2019532970A5

JP2019532970A5 JP2019521706A JP2019521706A JP2019532970A5 JP 2019532970 A5 JP2019532970 A5 JP 2019532970A5 JP 2019521706 A JP2019521706 A JP 2019521706A JP 2019521706 A JP2019521706 A JP 2019521706A JP 2019532970 A5 JP2019532970 A5 JP 2019532970A5

Authority

JP

Japan

Prior art keywords

amino acid

seq

complementarity determining

dose

chain complementarity

Prior art date

2017-10-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001413 amino acids Chemical group 0.000 claims description 162
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 126
• 230000037396 body weight Effects 0.000 claims description 37
• 239000000203 mixture Substances 0.000 claims description 32
• 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 30
• 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 26
• 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 26
• 229960003130 interferon gamma Drugs 0.000 claims description 23
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 21
• 239000000243 solution Substances 0.000 claims description 20
• 102000008070 Interferon-gamma Human genes 0.000 claims description 15
• 108010074328 Interferon-gamma Proteins 0.000 claims description 15
• 238000002347 injection Methods 0.000 claims description 11
• 239000007924 injection Substances 0.000 claims description 11
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
• 230000001064 anti-interferon Effects 0.000 claims description 8
• 208000014673 secondary hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 8
• 206010052779 Transplant rejections Diseases 0.000 claims description 6
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
• 229960003957 dexamethasone Drugs 0.000 claims description 6
• 238000002648 combination therapy Methods 0.000 claims description 5
• 238000009097 single-agent therapy Methods 0.000 claims description 5
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
• 208000031287 Primary hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 4
• 239000003795 chemical substances by application Substances 0.000 claims description 4
• 208000014681 genetic hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 4
• 239000002244 precipitate Substances 0.000 claims description 4
• 239000011780 sodium chloride Substances 0.000 claims description 4
• CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims description 2
• 208000026326 Adult-onset Still disease Diseases 0.000 claims description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
• 206010061192 Haemorrhagic fever Diseases 0.000 claims description 2
• 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims description 2
• 210000001185 bone marrow Anatomy 0.000 claims description 2
• 238000002659 cell therapy Methods 0.000 claims description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
• 208000035475 disorder Diseases 0.000 claims description 2
• 238000009472 formulation Methods 0.000 claims description 2
• 208000024908 graft versus host disease Diseases 0.000 claims description 2
• 229960002885 histidine Drugs 0.000 claims description 2
• 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
• 230000001861 immunosuppressant effect Effects 0.000 claims description 2
• 239000003018 immunosuppressive agent Substances 0.000 claims description 2
• 210000004738 parenchymal cell Anatomy 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
• 229920000053 polysorbate 80 Polymers 0.000 claims description 2
• 229940068968 polysorbate 80 Drugs 0.000 claims description 2
• 201000000306 sarcoidosis Diseases 0.000 claims description 2
• 208000035809 Lymphohistiocytosis Diseases 0.000 claims 12
• 239000008280 blood Substances 0.000 claims 12
• 210000004369 blood Anatomy 0.000 claims 12
• 239000000463 material Substances 0.000 claims 4
• 239000000047 product Substances 0.000 claims 2
• 230000003110 anti-inflammatory effect Effects 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 56
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1